WST Research Note — Growth Meets a Credibility Test
West Pharmaceutical’s strong quarter meets a harder test from valuation, market structure and unresolved oral-drug substitution risk.
Market Outlooks
WST Deep Coverage Review — Analysis as of July 27, 2026
West Pharmaceutical’s beat-and-raise supports the recovery thesis, but a heavy-volume reversal and oral-drug substitution risk keep confirmation incomplete.
Why Two Similar Markets Rarely Deserve Equal Weight
Correlated instruments travel together until they separate, and the moment of separation is usually more informative than either one on its own. This note describes how the CAMS desk reads that gap.
MOH Research Note — The Beat Masks Strain
Molina’s earnings beat and raised outlook face a harder test from weak premium revenue, declining membership and sharply compressed margins.
MOH Deep Coverage Review — Analysis as of July 27, 2026
Molina’s earnings beat masks weaker premium revenue, declining membership and compressed margins while the shares lag a strong health-care tape.
Closing Market Recap — Monday, July 27, 2026
Closing Market Recap for Monday, July 27, 2026. How the day closed: indexes, leaders, laggards, and volatility.
Desk Note — NVIDIA’s $5B SSI Bet · Jul 27
NVIDIA’s $5 billion SSI investment supports Vera Rubin demand while raising capital-allocation and customer-independence questions.
Weekly Market Outlook — Week of July 27, 2026: Rotation Waits on the Fed, Breadth Holds the Line
Leadership rotated from technology toward energy, health care, and financials while the long-term trend held ahead of Thursday’s Federal Reserve decision.
ASML Research Note — Monopoly Quality Needs Confirmation
ASML’s monopoly remains intact, but bookings evidence and China-policy exposure must confirm the next phase of the equipment cycle.
ASML Deep Coverage Review — Analysis as of July 27, 2026
ASML’s monopoly and margins remain formidable, but bookings gaps and China-policy uncertainty leave the near-term cycle unconfirmed.